Cell
Volume 147, Issue 2, 14 October 2011, Pages 306-319
ArticleTargeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Under a Creative Commons license
open access
Graphical Abstract
Highlights
► The SH2-kinase domain interface is necessary for high catalytic activity of Bcr-Abl ► This intramolecular interaction is critical for Bcr-Abl-dependent leukemogenesis ► Disrupting this interaction potentiates the effects of clinical kinase inhibitors ► Targeting of the SH2-kinase interface with a monobody inhibits Bcr-Abl allosterically
Cited by (0)
- 8
These authors contributed equally to this work
- 9
Present address: Ecole polytechnique fédérale de Lausanne (EPFL), Swiss Institute for Experimental Cancer Research (ISREC), 1015 Lausanne, Switzerland
- 10
Present address: Translational Oncology, Institute of Animal Breeding and Genetics, Veterinary Medical University of Vienna, A-1210 Vienna, Austria
Copyright © 2011 Elsevier Inc.